Key Points Eli Lilly is at the forefront of both diabetes and obesity medications. The pharmaceutical giant has offered strong guidance for the end of 2025. Looking ahead, it seems likely that demand in these key categories will continue. 10 stocks we like better than Eli Lilly › When I last wrote about Eli Lilly (NYSE: LLY) back in September, the shares were only slightly positive for the year. My view at the time was straightforward: This was a stock that just about every long-term investor sho ...